Bristol Myers Squibb Pre-Tax Profit Margin 2006-2021 | BMY

Current and historical pre-tax profit margin for Bristol Myers Squibb (BMY) from 2006 to 2021. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue. Bristol Myers Squibb pre-tax profit margin for the three months ending September 30, 2021 was .
Bristol Myers Squibb Pre-Tax Profit Margin Historical Data
Date TTM Revenue TTM Pre-Tax Income Pre-Tax Margin
2021-09-30 $45.47B $-4.21B -9.26%
2021-06-30 $44.38B $-4.11B -9.26%
2021-03-31 $42.81B $-4.04B -9.43%
2020-12-31 $42.52B $-6.87B -16.16%
2020-09-30 $39.40B $3.45B 8.76%
2020-06-30 $34.86B $2.54B 7.29%
2020-03-31 $31.01B $2.69B 8.68%
2019-12-31 $26.15B $4.98B 19.03%
2019-09-30 $24.17B $6.61B 27.34%
2019-06-30 $23.86B $7.43B 31.13%
2019-03-31 $23.29B $6.17B 26.49%
2018-12-31 $22.56B $5.97B 26.45%
2018-09-30 $22.04B $5.16B 23.42%
2018-06-30 $21.60B $4.18B 19.34%
2018-03-31 $21.04B $4.96B 23.55%
2017-12-31 $20.78B $5.13B 24.70%
2017-09-30 $20.57B $5.52B 26.83%
2017-06-30 $20.24B $5.90B 29.13%
2017-03-31 $19.97B $6.22B 31.13%
2016-12-31 $19.43B $5.92B 30.45%
2016-09-30 $18.47B $4.42B 23.92%
2016-06-30 $17.62B $3.85B 21.84%
2016-03-31 $16.91B $2.28B 13.51%
2015-12-31 $16.56B $2.08B 12.54%
2015-09-30 $16.53B $2.43B 14.68%
2015-06-30 $16.38B $2.45B 14.94%
2015-03-31 $16.11B $2.84B 17.65%
2014-12-31 $15.88B $2.38B 14.99%
2014-09-30 $16.06B $3.31B 20.61%
2014-06-30 $16.21B $3.12B 19.25%
2014-03-31 $16.37B $3.20B 19.57%
2013-12-31 $16.39B $2.89B 17.64%
2013-09-30 $16.14B $2.54B 15.71%
2013-06-30 $15.81B $0.46B 2.90%
2013-03-31 $16.20B $0.99B 6.09%
2012-12-31 $17.62B $2.34B 13.28%
2012-09-30 $18.88B $3.42B 18.12%
2012-06-30 $20.49B $6.51B 31.77%
2012-03-31 $21.48B $7.24B 33.70%
2011-12-31 $21.24B $6.98B 32.86%
2011-09-30 $20.90B $6.80B 32.53%
2011-06-30 $20.35B $6.58B 32.35%
2011-03-31 $19.69B $6.39B 32.44%
2010-12-31 $19.48B $6.07B 31.16%
2010-09-30 $19.41B $5.98B 30.80%
2010-06-30 $19.40B $5.93B 30.57%
2010-03-31 $19.29B $5.86B 30.37%
2009-12-31 $18.81B $5.60B 29.79%
2009-09-30 $16.14B $5.48B 33.92%
2009-06-30 $16.61B $5.07B 30.50%
2009-03-31 $17.15B $4.76B 27.78%
2008-12-31 $17.72B $4.78B 26.96%
2008-09-30 $17.58B $3.01B 17.14%
2008-06-30 $16.92B $3.11B 18.40%
2008-03-31 $16.19B $2.88B 17.78%
2007-12-31 $15.62B $2.52B 16.16%
2007-09-30 $15.90B $2.26B 14.20%
2007-06-30 $15.45B $1.62B 10.48%
2007-03-31 $15.85B $1.74B 11.00%
2006-12-31 $16.21B $2.09B 12.86%
2006-09-30 $18.12B $3.54B 19.54%
2006-06-30 $18.73B $4.55B 24.29%
2006-03-31 $18.75B $4.57B 24.37%
2005-12-31 $18.61B $4.30B 23.13%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $141.747B $42.518B
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes and sells biopharmaceutical products. It offers products which includes hematology, oncology, cardiovascular and immunology. Bristol-Myers Squibb Company, formerly known as Bristol-Myers Company, is based in New York.
Stock Name Country Market Cap PE Ratio
Bio-Rad Laboratories (BIO.B) United States $17.038B 34.58
QIAGEN (QGEN) Netherlands $10.791B 18.27
Biohaven Pharmaceutical Holding (BHVN) United States $7.896B 0.00
Emergent Biosolutions (EBS) United States $2.380B 8.56
Arcus Biosciences (RCUS) United States $2.057B 0.00
Myovant Sciences (MYOV) United Kingdom $1.157B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.011B 0.00
Zymeworks (ZYME) Canada $0.386B 0.00
Ambrx Biopharma (AMAM) United States $0.188B 0.00
SQZ Biotechnologies (SQZ) United States $0.178B 0.00
Enzo Biochem (ENZ) United States $0.154B 19.88